NCT00434746View on ClinicalTrials.gov

Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Healthy
Interventions
DRUG

ILV-094

Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo

Trial Locations (1)

171-0014

Ikebukuro

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00434746 - Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects | Biotech Hunter | Biotech Hunter